tesaglitazar has been researched along with Cardiac Failure in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Area-Gomez, E; Chin, A; Civelek, M; Drosatos, K; Goldberg, IJ; Kalliora, C; Kyriazis, ID; Lieu, MJ; Madesh, M; Mizushima, W; Oka, SI; Pol, CJ; Sadoshima, J; Scerbo, D; Schulze, PC; Tian, Y; Yue, Y | 1 |
1 other study(ies) available for tesaglitazar and Cardiac Failure
Article | Year |
---|---|
Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
Topics: Alkanesulfonates; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisomes; Phenylpropionates; PPAR alpha; PPAR gamma; Receptors, Leptin; Sirtuin 1; Transcription Factors; Transcriptome | 2019 |